NSABP近十年乳腺癌临床试验进展

近十年来,美国国家乳腺和肠道外科辅助治疗研究组公布的研究结果继续改变着早期乳腺癌的临床实践:前哨淋巴结活检成为新的外科操作标准,芳香化酶抑制剂辅助内分泌治疗从5年延长到10年可使高危高激素反应人群获益,化疗联合曲妥珠单抗成为人类表皮生长因子受体-2阳性浸润性乳腺癌标准辅助治疗策略.此外,其研究进展还涉及术后辅助化疗、新辅助化疗方案优化等领域.

Advances of NSABP breast cancer trails in the past decade

The research findings published by National Surgical Adjuvant Breast and Bowel Project have continued to change the clinical practice of early-stage breast cancer over the past decade.Sentinel lymph node biopsy has become the new surgical operation standard.The aromatase inhibitor adjuvant endocrine therapy cycle has been extended from 5 years to 10 years, which benefits the patients with high risk and reactivity.Chemotherapy combined with trastuzumab has become the standard adjuvant therapy strategy of human epidermal growth factor receptor-2-positive invasive breast cancer.In addition, the research progress is also related to the optimization of the fields including the postoperative adjuvant chemotherapy and neoadjuvant chemotherapy.